ArticleFrontiers in medicine2026
Predictive value of uric acid and lactate dehydrogenase for maternal morbidity in preeclampsia: a retrospective case-control study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Preeclampsia is a major cause of global maternal morbidity and mortality. This study aims to determine whether readily available and inexpensive biomarkers, serum uric acid (UA), and lactate dehydrogenase (LDH), show a significant association with severe maternal morbidity in established preeclampsia. Materials and methods: In this retrospective Case-Control study (2017-2022), 200 singleton pregnancies with ACOG-defined preeclampsia and 200 age and gestational age-comparable healthy controls delivered at a tertiary center were analyzed. UA and LDH were serially measured (minimum, average, maximum). Maternal morbidities (acute kidney injury, pulmonary oedema, neurological seizures, vision loss) were adjudicated using KDIGO, Berlin and ACOG criteria. Exclusions: HELLP syndrome, chronic hypertension, diabetes, renal/liver/cardiac disease, systemic infection. Multivariable logistic regression adjusted for age, BMI, parity, and mean systolic BP. Results: Mean UA (5.8 ± 1.3 vs. 4.4 ± 1.1 mg/dL) and LDH (410.7 ± 194.0 vs. 267.2 ± 92.0 IU/L) were higher in preeclampsia ( Conclusion: In a Middle Eastern cohort, UA is an inexpensive, widely available marker that is significantly associated with severe maternal morbidity in established preeclampsia, whereas LDH, while reflecting disease severity, did not add independent predictive value for most outcomes after adjustment. Prospective multicentre validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.